Shigamabs PII/PIII
https://www.fda.gov/ohrms/dockets/AC/07/slides/2007-4286s1-07-thallion-cleary.pdf
This PII/PIII design was accepted by FDA last year. Waiting to initiate trial.
Quite straigth forward trial.
I wonder why no one has partnered this drug.
Emergency rooms (hospital and clinics) world wide will be forced to stock a minimal quantity of Shigamabs. Shigamabs shelf life is 2 years and basically people will need to replace the stocks.
would be Immoral not to stock Shigamabs...
Relatively small trial - cost should be max 40 Millions.
Market size could be significative Loewens said recurring inventory sales could be 55 millions X 7 years tax free.